140 related articles for article (PubMed ID: 33073806)
1. Interaction of macrocyclic gadolinium-based MR contrast agents with Type I collagen. Equilibrium and kinetic studies.
Guidolin N; Travagin F; Giovenzana GB; Vágner A; Lotti S; Chianale F; Brücher E; Maisano F; Kirchin MA; Tedoldi F; Giorgini A; Colombo Serra S; Baranyai Z
Dalton Trans; 2020 Nov; 49(42):14863-14870. PubMed ID: 33073806
[TBL] [Abstract][Full Text] [Related]
2. [Gd(HB-DO3A)]: Equilibrium, Dissociation Kinetic and Structural Differences in a Simple Homolog of [Gd(HP-DO3A)] (Prohance
Versolatto S; Boccalon M; Guidolin N; Travagin F; Alessio E; Aime S; Balducci G; Giovenzana GB; Baranyai Z
Chemistry; 2024 May; 30(28):e202400344. PubMed ID: 38469901
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats.
Bussi S; Coppo A; Bonafè R; Rossi S; Colombo Serra S; Penard L; Kirchin MA; Maisano F; Tedoldi F
J Magn Reson Imaging; 2021 Nov; 54(5):1636-1644. PubMed ID: 33973290
[TBL] [Abstract][Full Text] [Related]
4. Signal Enhancement and Enhancement Kinetics of Gadobutrol, Gadoteridol, and Gadoterate Meglumine in Various Body Regions: A Comparative Animal Study.
Knobloch G; Frenzel T; Pietsch H; Jost G
Invest Radiol; 2020 Jun; 55(6):367-373. PubMed ID: 31985602
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
Chandrasekharan P; Yong CX; Poh Z; He T; He Z; Liu S; Robins EG; Chuang KH; Yang CT
Biomaterials; 2012 Dec; 33(36):9225-31. PubMed ID: 23026708
[TBL] [Abstract][Full Text] [Related]
6. Gd-complexes of macrocyclic DTPA conjugates of 1,1'-bis(amino)ferrocenes as high relaxivity MRI blood-pool contrast agents (BPCAs).
Kim HK; Park JA; Kim KM; Nasiruzzaman SM; Kang DS; Lee J; Chang Y; Kim TJ
Chem Commun (Camb); 2010 Nov; 46(44):8442-4. PubMed ID: 20886175
[TBL] [Abstract][Full Text] [Related]
7. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats.
Bussi S; Coppo A; Botteron C; Fraimbault V; Fanizzi A; De Laurentiis E; Colombo Serra S; Kirchin MA; Tedoldi F; Maisano F
J Magn Reson Imaging; 2018 Mar; 47(3):746-752. PubMed ID: 28730643
[TBL] [Abstract][Full Text] [Related]
8. Editorial for "Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine and Gadobutrol to rats".
Liang X; Yeh CH
J Magn Reson Imaging; 2021 Nov; 54(5):1645-1646. PubMed ID: 34046961
[No Abstract] [Full Text] [Related]
9. Optimizing the high-field relaxivity by self-assembling of macrocyclic Gd(III) complexes.
Lawson D; Barge A; Terreno E; Parker D; Aime S; Botta M
Dalton Trans; 2015 Mar; 44(11):4910-7. PubMed ID: 25411928
[TBL] [Abstract][Full Text] [Related]
10. Relaxivity of Gd-Based MRI Contrast Agents in Crosslinked Hyaluronic Acid as a Model for Tissues.
Fragai M; Ravera E; Tedoldi F; Luchinat C; Parigi G
Chemphyschem; 2019 Sep; 20(17):2204-2209. PubMed ID: 31298452
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Tweedle MF; Wedeking P; Kumar K
Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?
Bonafè R; Coppo A; Queliti R; Bussi S; Maisano F; Kirchin MA; Tedoldi F
Eur Radiol Exp; 2023 Mar; 7(1):7. PubMed ID: 36855001
[TBL] [Abstract][Full Text] [Related]
13. Inter-individual Comparison of Gadobutrol and Gadoteridol Tissue Time-intensity Profiles for Dynamic Susceptibility Contrast Perfusion MR Imaging.
Yamada M; Taoka T; Kawaguchi A; Yasuda K; Niinomi Y; Ohashi Y; Okuda T; Naganawa S
Magn Reson Med Sci; 2019 Jan; 18(1):75-81. PubMed ID: 29794406
[TBL] [Abstract][Full Text] [Related]
14. Unexpected aggregation of neutral, xylene-cored dinuclear GdIII chelates in aqueous solution.
Costa J; Balogh E; Turcry V; Tripier R; Le Baccon M; Chuburu F; Handel H; Helm L; Tóth E; Merbach AE
Chemistry; 2006 Sep; 12(26):6841-51. PubMed ID: 16770815
[TBL] [Abstract][Full Text] [Related]
15. Cyclen-based Gd
Rashid HU; Martines MAU; Jorge J; de Moraes PM; Umar MN; Khan K; Rehman HU
Bioorg Med Chem; 2016 Nov; 24(22):5663-5684. PubMed ID: 27729196
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
Lancelot E
Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
[TBL] [Abstract][Full Text] [Related]
17. A multiple gadolinium complex decorated fullerene as a highly sensitive T(1) contrast agent.
Wang L; Zhu X; Tang X; Wu C; Zhou Z; Sun C; Deng SL; Ai H; Gao J
Chem Commun (Camb); 2015 Mar; 51(21):4390-3. PubMed ID: 25676633
[TBL] [Abstract][Full Text] [Related]
18. The Macrocyclic Gadolinium-Based Contrast Agents Gadobutrol and Gadoteridol Show Similar Elimination Kinetics From the Brain After Repeated Intravenous Injections in Rabbits.
Frenzel T; Ulbrich HF; Pietsch H
Invest Radiol; 2021 Jun; 56(6):341-347. PubMed ID: 33259443
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents.
Tweedle MF
Invest Radiol; 1992 Aug; 27 Suppl 1():S2-6. PubMed ID: 1506149
[No Abstract] [Full Text] [Related]
20. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
